tradingkey.logo

Dexcom Inc

DXCM
查看詳細走勢圖
66.060USD
+0.150+0.23%
收盤 12/19, 16:00美東報價延遲15分鐘
25.76B總市值
35.86本益比TTM

Dexcom Inc

66.060
+0.150+0.23%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.23%

5天

-1.34%

1月

+10.60%

6月

-18.45%

今年開始到現在

-15.06%

1年

-12.87%

查看詳細走勢圖

TradingKey Dexcom Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Dexcom Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名28/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價86.34。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Dexcom Inc評分

相關信息

行業排名
28 / 208
全市場排名
97 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 31 分析師
買入
評級
86.336
目標均價
+31.57%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Dexcom Inc亮點

亮點風險
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
業績高增長
公司營業收入穩步增長,連續3年增長38.60%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入4.03B美元
估值低估
公司最新PE估值35.86,處於3年歷史低位
機構加倉
最新機構持股388.08M股,環比增加0.05%
ETHSX持倉
明星投資者ETHSX持倉,最新持倉103.84K股

Dexcom Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Dexcom Inc簡介

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
公司代碼DXCM
公司Dexcom Inc
CEOMr. Jacob Steven (Jake) Leach
網址https://www.dexcom.com/

常見問題

Dexcom Inc(DXCM)的當前股價是多少?

Dexcom Inc(DXCM)的當前股價是 66.060。

Dexcom Inc 的股票代碼是什麼?

Dexcom Inc的股票代碼是DXCM。

Dexcom Inc股票的52週最高點是多少?

Dexcom Inc股票的52週最高點是93.250。

Dexcom Inc股票的52週最低點是多少?

Dexcom Inc股票的52週最低點是54.110。

Dexcom Inc的市值是多少?

Dexcom Inc的市值是25.76B。

Dexcom Inc的淨利潤是多少?

Dexcom Inc的淨利潤為576.20M。

現在Dexcom Inc(DXCM)的股票是買入、持有還是賣出?

根據分析師評級,Dexcom Inc(DXCM)的總體評級為買入,目標價格為86.336。

Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是多少

Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是1.842。
KeyAI